Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 1.8%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) dropped 1.8% during trading on Friday . The company traded as low as $3.25 and last traded at $3.25. Approximately 4,424 shares were traded during trading, a decline of 75% from the average daily volume of 17,575 shares. The stock had previously closed at $3.31.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a research report on Friday, March 22nd.

Armata Pharmaceuticals Stock Down 1.8 %

The firm has a market capitalization of $117.49 million, a PE ratio of -1.64 and a beta of 0.85.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.55) earnings per share for the quarter. The business had revenue of $1.53 million during the quarter, compared to the consensus estimate of $0.68 million. Armata Pharmaceuticals had a negative return on equity of 280.95% and a negative net margin of 1,524.51%. Analysts anticipate that Armata Pharmaceuticals, Inc. will post -1.34 earnings per share for the current year.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ARMP. Vanguard Group Inc. increased its position in shares of Armata Pharmaceuticals by 59.5% during the 4th quarter. Vanguard Group Inc. now owns 145,078 shares of the company's stock valued at $470,000 after purchasing an additional 54,109 shares during the last quarter. HRT Financial LP purchased a new stake in Armata Pharmaceuticals during the 4th quarter valued at about $52,000. Jane Street Group LLC purchased a new stake in Armata Pharmaceuticals during the 4th quarter valued at about $25,000. Northern Trust Corp purchased a new stake in Armata Pharmaceuticals during the 1st quarter valued at about $95,000. Finally, Renaissance Technologies LLC boosted its holdings in Armata Pharmaceuticals by 5.6% during the 4th quarter. Renaissance Technologies LLC now owns 73,696 shares of the company's stock valued at $91,000 after acquiring an additional 3,900 shares during the period. 3.57% of the stock is currently owned by institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.